Navigation Links
Bedford Laboratories(TM) to Begin Shipping Sumatriptan Succinate Injection
Date:2/25/2009

BEDFORD, Ohio, Feb. 25 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., today announced the launch of Sumatriptan Succinate Injection. This product is AP rated and is equivalent to Imitrex(R) by GlaxoSmithKline. Sumatriptan is a vascular headache suppressant indicated for 1) the acute treatment of migraine attacks with or without aura and 2) the acute treatment of cluster headache episodes. Sumatriptan Succinate Injection is not for use in the management of hemiplegic or basilar migraine.

(LOGO: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO)

Bedford Laboratories will supply Sumatriptan Succinate Injection as a sterile aqueous solution in a 6mg (Base) / 0.5mL single-dose vial packaged in cartons containing 10 vials.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169 or at www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim Corporation

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on the Boehringer Ingelheim Corporation, please visit http://us.boehringer-ingelheim.com.

Imitrex is a registered trademark of GlaxoSmithKline


'/>"/>
SOURCE Bedford Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bedford Laboratories(TM) to Begin Shipping Irinotecan HCl Injection
2. Children of New Bedford Immigrant Raids Are Victims of Terrorism, Testifies Dr. Laria Today
3. Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution
4. MidMichigan Health Cuts Out Trans Fats Beginning March 1
5. Disability Community Humble Beginnings Lead to Great Things at Disabled World
6. Perrigo Begins Shipments of Ibuprofen PM
7. Governor Crist Proclaims Tobacco Free Florida Week Beginning February 27
8. Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors
9. First Electronic Healthcare Network in the U.S. Begins Operations in Buffalo, NY
10. U.S. Labor Department to begin new monthly data series on people with disabilities from Current Population Survey on Feb. 6
11. Milkscreen Home Test for Alcohol in Breast Milk Begins Nationwide Sales at Walgreens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CO (PRWEB) , ... March 28, 2017 , ... ... reasonable assumption that in order to improve teacher quality, the field must first ... swinging from one popular reform to the next” and that decades of input- ...
(Date:3/28/2017)... NEW YORK (PRWEB) , ... March 28, 2017 ... ... development, NTX Technology™, is the first technology to directly address the resolution to ... Organization. NTX Technology™ is a patented compound of FDA and TTB approved ingredients ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... in state legislatures and Congress to protect parental rights and civil liberties, and ... safety in America. , The demonstration coincides with a press conference taking place ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... all holidays (IBT World Travel Trends Report). As travelers visit both urban destinations, ... in temperatures, and prolonged sun exposure. In response, the outdoor industry has blurred ...
(Date:3/28/2017)... PA (PRWEB) , ... March 28, 2017 , ... ... for and by physicians, announced today the launch of a free, public-facing tool ... Via Cost Analyzer (VCA) was developed to provide comparative information to patients, providers, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017   Dynatronics Corporation (NASDAQ: ... Cynthia L. McHenry (Cyndi) as Vice ... leading Dynatronics manufacturing, distribution, and purchasing operations across ... CEO Kelvyn H. Cullimore, Jr. ... process conducted by the company as it continues ...
(Date:3/29/2017)... NetworkNewsWire Editorial Coverage  ... There are a number of advantages ... economic arguments also favor its legalization. The benefits include increased ... to legalize and regulate marijuana requires an ecosystem of support ... SING Profile ), American Cannabis Company (OTC: AMMJ), Kush Bottles, ...
(Date:3/29/2017)... AVIV, Israel , March 29, 2017 ... agreement in which Exeltis will obtain exclusive marketing rights for Neurim,s ... ... an age-appropriate drug targeted to treat sleep disorders in children with ... be the first sleep medication approved for children. The ...
Breaking Medicine Technology: